AIM ImmunoTech Inc. has announced the adjournment of its 2026 Annual Meeting of Stockholders due to a lack of quorum. The meeting, originally held on November 17, 2026, was unable to proceed because not enough shares were present or represented by proxy.

This decision is significant as it allows shareholders additional time to review proxy materials and submit their votes. The adjourned meeting is now scheduled to reconvene on December 8, 2026, at 11:00 A.M. Eastern Time, and will be conducted virtually.

According to the filing, the record date for stockholders entitled to vote remains September 28, 2026. No changes have been made to the proposals that will be voted on at the reconvened meeting. Shareholders who have already submitted their proxies do not need to take further action if they do not wish to change their votes.

Background

AIM ImmunoTech Inc. is a company listed on the NYSE under the ticker AIM and classified under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). The company, based in Ocala, Florida, focuses on the development of immunotherapeutic products to treat diseases.

What the Filing Says

The SEC filing states, "The Company did not have a sufficient number of shares of the Company’s common stock present or represented by proxy at the Annual Meeting to constitute a quorum." The filing further details that the adjournment aims to provide stockholders with additional time to review proxy materials.

Impact

This adjournment may affect shareholders who were eager to participate in the decision-making process regarding the company’s future. It reflects broader challenges within the biological products industry, where engaging shareholders can be difficult.

What's Next

The adjourned Annual Meeting will reconvene on December 8, 2026. The filing does not specify any further actions required from shareholders at this time.